Tag: Mash treatment

The FDA granted Rezdiffra accelerated approval in March 2024 as the first treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring. As MASH is a chronic condition, the question of how long do you take Rezdiffra is central for patients beginning this important long-term therapy. This article explores the factors influencing the duration of treatment.

As the first and only FDA-approved medication for MASH, Rezdiffra is available exclusively through a limited specialty pharmacy network, not from standard retail drugstores. This means patients prescribed Rezdiffra must go through a specific process involving their healthcare provider and the manufacturer's patient support program to access their medication.

With a wholesale acquisition cost of approximately $47,400 per year, Rezdiffra's price point has drawn significant attention. The question 'Why is Rezdiffra so expensive?' is answered by several factors, including its status as the first-in-class treatment for MASH, extensive research and development costs, and market exclusivity.